Dyve Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Dyve Biosciences's estimated annual revenue is currently $2.5M per year.
- Dyve Biosciences's estimated revenue per employee is $155,000
Employee Data
- Dyve Biosciences has 16 Employees.
- Dyve Biosciences grew their employee count by -33% last year.
Dyve Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Dyve Biosciences?
About Dyve Biosciences Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout. Dyve’s transdermal delivery science platform overturns the traditional limitations of administering therapies. It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs. For more information, please visit www.dyvebio.com. Corporate Contact Jim McGee Dyve Biosciences, Inc. 805-857-6449 jim.mcgee@dyvebio.com Investor Contact Corey Davis LifeSci Advisors, LLC 212-915-2577 cdavis@lifesciadvisors.com
keywords:N/A
N/A
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Thousand Oaks
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 16 | 0% | N/A |
#2 | $1.4M | 16 | N/A | N/A |
#3 | $2.5M | 16 | 7% | N/A |
#4 | $1.5M | 17 | -6% | N/A |
#5 | $1.5M | 17 | N/A | N/A |